BAG3’s Role in Indicating the Recurrence of TNBC
DOI:
https://doi.org/10.61173/b0h8my07Keywords:
-xenograft, triple-negative breast cancer (TNBC), BAG3, cancer recurrence, epidermal growth factor receptor (EGFR) pathway, cell proliferationAbstract
Triple-negative breast cancer (TNBC) cells tend to resist chemotherapy drugs, making it essential to find other therapies
to treat this aggressive cancer. The inhibition of BAG3 with YM-1 is an option because BAG3 is overexpressed in over
50% of TNBC patients. BAG3 positively regulates the EGFR pathway and cell proliferation, which means inhibiting it
could reduce TNBC tumor size and lessen the recurrence of TNBC. This paper looks at xenografting BT-549 cell lines
in mice and treating them with docetaxel, PBS, and YM-1 at various concentrations. Changes in the tumor are tracked
using the tumor volume and weight of the mice. The results of this work will provide a better understanding of how
BAG3 inhibition impacts cell proliferation and whether it can be an indicator of TNBC recurrence. Studying YM-1
gives patients more options and the chance to find the best treatment.
References
[1] Linder, B., et al., BAG3 is a negative regulator of ciliogenesis in glioblastoma and triple-negative breast cancer cells. J Cell Biochem, 2022. 123(1): p. 77-90.
[2] Das, C.K., et al., BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells. Neoplasia, 2018. 20(3): p. 263-279.
[3] Yin, L., et al., Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020. 22(1): p. 61.
[4] American Cancer Society. What is cancer recurrence? 2016, February 12; Available from: https://www.cancer. org/treatment/survivorship-during-and-after-treatment/ long-term-health-concerns/recurrence/what-is-cancerrecurrence.html#:~:text=If%20cancer%20is%20found%20 after,somewhere%20else%20in%20the%20body.
[5] Dent, R., et al., Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 2007. 13(15 Pt 1): p. 4429-34.
[6] Boiani, M., et al., The stress protein BAG3 stabilizes Mcl- 1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem, 2013. 288(10): p. 6980-90.
[7] Shields, S., et al., BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triplenegative breast cancer. Oncotarget, 2018. 9(21): p. 15673-15690.
[8] Lee, S., Jung, J., Lee, Y.-J., Kim, S.-K., Kim, J.-A., Kim, B.- K., Park, K. C., et al. (2021). Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer. Cancers, 13(12), 2987. MDPI AG.
[9] Li, Z.N., et al., BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy. Gastroenterol Rep (Oxf), 2020. 8(3): p. 192-205.
[10] Sun, Y., et al., FZD5 contributes to TNBC proliferation, DNA damage repair and stemness. Cell Death Dis, 2020. 11(12): p. 1060.
[11] Duan, H., et al., Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B, 2021. 11(1): p. 55-70.
[12] Colvin, T.A., et al., Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res, 2014. 74(17): p. 4731-40.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
